Literature DB >> 32938732

Evaluation of the Amplex eazyplex Loop-Mediated Isothermal Amplification Assay for Rapid Diagnosis of Pneumocystis jirovecii Pneumonia.

Timo Huber1, Annerose Serr2, Walter Geißdörfer1, Christina Hess2, Christian Lynker-Aßmus1, Friederike D von Loewenich3, Christian Bogdan1, Jürgen Held4.   

Abstract

Quantitative PCR (qPCR) assays are the gold standard for diagnosis of Pneumocystis jirovecii pneumonia (PCP). However, they are laborious and require skilled personnel. Therefore, execution outside regular working hours of the molecular biology laboratory is limited. The eazyplex P. jirovecii assay (PJA) uses loop-mediated isothermal amplification for detection of P. jirovecii It is performed directly with respiratory specimens, without the need for special skills, and delivers a result within 3 to 25 min. The goal of our study was to compare the performance of the eazyplex PJA with that of established P. jirovecii qPCR assays. All archived bronchoalveolar lavage fluid (BALF) samples that had previously tested positive for P. jirovecii by qPCR assay and 50 control samples (retrospective part), as well as all BALF samples received for P. jirovecii analysis over a period of 4 months (prospective part), were tested. Forty-nine patients with proven PCP and 126 patients without PCP were included. The sensitivity and specificity of the eazyplex PJA (95.7% and 96.5%, respectively) were comparable to those for three different P. jirovecii qPCR assays. The detection limit of the eazyplex PJA was analogous to 103 copies of the major surface glycoprotein gene per 25 μl of BALF, corresponding to 10 to 20 P. jirovecii cells. The eazyplex PJA reliably discriminated patients with PCP from patients with P. jirovecii colonization. It delivered a positive result within a mean of 9 min 38 s and required a hands-on time of 2 min 45 s. In summary, the eazyplex PJA showed identical performance for the diagnosis of PCP, compared to qPCR assays. However, in terms of time to result, practicability, and robustness, the eazyplex PJA is clearly superior and allows for around-the-clock molecular testing.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  AIDS; BALF; HIV; LAMP; NAT; PCP; PCR; Pneumocystis cariniizzm321990; point-of-care

Year:  2020        PMID: 32938732      PMCID: PMC7685886          DOI: 10.1128/JCM.01739-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Quantitative TaqMan PCR for detection of Pneumocystis jiroveci.

Authors:  Françoise Brancart; Hector Rodriguez-Villalobos; Pierre-Alain Fonteyne; Daliana Peres-Bota; Corinne Liesnard
Journal:  J Microbiol Methods       Date:  2005-06       Impact factor: 2.363

Review 2.  [Pneumocystis jirovecii pneumonia-an opportunistic infection undergoing change].

Authors:  F Hitzenbichler; A Mohr; B Salzberger
Journal:  Internist (Berl)       Date:  2019-07       Impact factor: 0.743

3.  Serum (1 → 3)-β-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value.

Authors:  J Held; M S Koch; U Reischl; T Danner; A Serr
Journal:  Clin Microbiol Infect       Date:  2011-04       Impact factor: 8.067

4.  Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia.

Authors:  Hans Henrik Larsen; Henry Masur; Joseph A Kovacs; Vee J Gill; Victoria A Silcott; Palaniandy Kogulan; Janine Maenza; Margo Smith; Daniel R Lucey; Steven H Fischer
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients.

Authors:  Georg Maschmeyer; Jannik Helweg-Larsen; Livio Pagano; Christine Robin; Catherine Cordonnier; Peter Schellongowski
Journal:  J Antimicrob Chemother       Date:  2016-05-12       Impact factor: 5.790

6.  Comparison of the FXG™: RESP (Asp+) real-time PCR assay with direct immunofluorescence and calcofluor white staining for the detection of Pneumocystis jirovecii in respiratory specimens.

Authors:  Christine Seah; Susan E Richardson; George Tsui; Billy Yu; John Thornback; Lisa McTaggart; Andrea Boggild; Nancy L Wengenack; Sean X Zhang
Journal:  Med Mycol       Date:  2011-08-23       Impact factor: 4.076

7.  ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

Authors:  Alexandre Alanio; Philippe M Hauser; Katrien Lagrou; Willem J G Melchers; Jannik Helweg-Larsen; Olga Matos; Simone Cesaro; Georg Maschmeyer; Hermann Einsele; J Peter Donnelly; Catherine Cordonnier; Johan Maertens; Stéphane Bretagne
Journal:  J Antimicrob Chemother       Date:  2016-05-12       Impact factor: 5.790

8.  Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole.

Authors:  Hideaki Kato; Sei Samukawa; Hiroyuki Takahashi; Hideaki Nakajima
Journal:  J Infect Chemother       Date:  2019-07-09       Impact factor: 2.211

9.  Variation in the major surface glycoprotein genes in Pneumocystis jirovecii.

Authors:  Geetha Kutty; Frank Maldarelli; Guillaume Achaz; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

10.  Prevalence and genotype distribution of Pneumocystis jirovecii in Cuban infants and toddlers with whooping cough.

Authors:  Ernesto X Monroy-Vaca; Yaxsier de Armas; María T Illnait-Zaragozí; Gilda Toraño; Raúl Diaz; Dania Vega; Ileana Alvarez-Lam; Enrique J Calderón; Christen R Stensvold
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.